Enes Erul, Oncology Fellow at Ankara University, shared a post on LinkedIn:
“I’m happy to share that our review, prepared together with my inspiring colleagues from IDEA, has been published. Conquer Cancer, the ASCO Foundation, Sergio Cifuentes-Canaval, Dr Akhil Santhosh (MD, DM Med Onc, MRCP UK), Emir Sokolović
In this paper, we provide a comprehensive overview of FGFR inhibitors in cholangiocarcinoma, covering:
- The molecular background (especially FGFR2 alterations),
- Clinical efficacy data,
- Toxicity management (particularly hyperphosphatemia),
- Acquired resistance mechanisms, and
- The role of liquid biopsy/cfDNA in tracking resistance mutations. International Society of Liquid Biopsy
We also highlight that much of the current evidence comes from single-arm and relatively small studies, underlining the need for stronger prospective data, better patient selection, and rational combination strategies.
I would especially like to thank the mentors I always feel grateful for—particularly Pınar Kubilay Tolunay and Alessandro Rizzo – for their support, guidance, and inspiration throughout this journey. Thanks to Ankara University
Grateful as well to my IDEA colleagues and co-authors for this meaningful collaboration.”
Title: Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps
Authors: Erul E, Cifuentes-Canaval S , Santhosh A, Sokolović E , Della Mura M, Cazzato G, Kubilay Tolunay P, Rizzo A.
Other articles featuring Enes Erul on OncoDaily.
